Please Wait...

Imaging Modalities

Medical and Diagnostic Imaging Modalities

Bioclinica has extensive experience with medical imaging and diagnostic imaging modalities for clinical trials.

CT

  • Angiography (CTA)
  • Lung Density/Volume
  • Quantitative Computed Tomography (QCT)

DXA

  • Bone Mineral Density (BMD)
  • Body Composition
  • Hip Structural Analysis (HSA)

MRI

  • Angiography (MRA)
  • Body and Neuro
  • Cardiac MRI
  • Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI)

Nuclear Medicine

  • Planar
  • Multi-Gated Acquisition Scan (MUGA)
  • Single Photon Emission Computed Tomography (SPECT)
  • Whole Body
  • PET
  • PET/CT

OCT

  • Retinal thickness and volume
  • Retinal Nerve Fiber layer (RNFL) thickness
  • Macular holes and puckers

Ultrasound

  • Abdominal/small parts Ultrasound
  • Echocardiography
  • FMD (flow mediated dilation)
  • Duplex
  • Duplex Doppler
  • CEUS (Contrast Enhanced Ultrasound)
  • B-Mode and M-Mode

X-Ray

  • General
  • Angiography
  • Mammography

Want to learn more about how Bioclinica’s medical and diagnostic imaging modalities solutions can benefit your clinical studies? Request a demo today!

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Bioclinica is organized into three business segments so that we can provide expert service and multifaceted technologies. Our Medical Imaging & Biomarkers segment includes an Imaging Core Lab, a Cardiovascular Safety division, and a Molecular Marker Laboratory. Our eHealth segment comprises eClinical Solutions, Randomization & Trial Supply Management, Safety & Regulatory Solutions, and Financial Lifecycle Solutions. Under the Global Clinical Research segment, we offer a network of research sites, patient recruitment, and a Post-Approval Research division.

Our Medical Imaging team is in the spotlight for a job well done! https://t.co/fkmt0zvPhf https://t.co/D7YMTeiSd3
bioclinica (2 days ago)
RT @melfass: "What this agreement means is that we can allocate scarce resources to areas of higher risk" @US_FDA on MRA with @EMA_News at…
bioclinica (3 days ago)
RT @DrugInfoAssn: What has been the biggest takeway for your organization so far? Tweet @ us using #DIA2017
bioclinica (5 days ago)
"Q" on #RBM & Total Quality Mgmt? @Kristin_Mauri has "A" @DrugInfoAssn #DIA2017 https://t.co/MqCxkmAfa0
bioclinica (5 days ago)
Kristen Mauri shows the @DIA audience the value of risk based monitoring https://t.co/ssJCfc9gQ5
bioclinica (5 days ago)
Innovation Theater Kristin Mauri of @bioclinica presenting on RBM & TQM @DrugInfoAssn #DIA2017 https://t.co/zsGroQcpiU
bioclinica (5 days ago)

Latest Blogs: